AN ACT CONCERNING HEALTH INSURANCE COVERAGE OF ORALLY AND INTRAVENOUSLY ADMINISTERED MEDICATIONS.
Do you support it?
Want to know if it passes?
We'll email you when SB 21 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on SB 21.
You're tracking SB 21
We'll email you the moment it moves.
SB 21 — AN ACT CONCERNING HEALTH INSURANCE COVERAGE OF ORALLY AND INTRAVENOUSLY ADMINISTERED MEDICATIONS.
Last action — FAV. CHG. OF REF., SEN. TO COMM. ON Appropriations
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
2In Committee
-
3Passed Senate
-
4Passed House
-
5To Executive
-
6Enacted
This bill died with 2017 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Bill Text
What changed in the latest version
4 added · 7 removedPlain-language change summary
The amendment specifies that health insurance policies providing coverage for prescription drugs must also cover intravenously administered drugs in a manner that is at least as favorable as coverage for orally administered drugs. This change matters because it aims to ensure that patients receive equitable insurance coverage regardless of the method of drug administration.
4432 *04432SB00021INS**_____SB00021INSAPP030817____* Referred to Committee on INSURANCE AND REAL ESTATE Introduced by:
2 January 1, 2018 New section StatementINS ofJoint Purpose:Favorable C/R APP
To require health insurance policies that provide coverage for prescription drugs to provide coverage for intravenously administered drugs on a basis no less favorable than orally administered drugs.
[Proposed deletions are enclosed in brackets.
Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.] Co-Sponsors:
SEN.
LOONEY, 11th Dist.
S.B.
21
View plain text versions (3)
- R02 html
- R01 html
- R00 Current html
Action History
-
FAV. CHG. OF REF., SEN. TO COMM. ON Appropriations
-
RPTD. OUT OF LCO
-
FILED WITH LCO
-
Joint Favorable Change of Reference APP
-
REF. TO JOINT COMM. ON Insurance and Real Estate
-
DRAFTED BY COMMITTEE
-
Vote to Draft
-
PUBLIC HEARING 0207
-
Reserved for Subject Matter Public Hearing
-
REF. TO JOINT COMM. ON Insurance and Real Estate
Sponsors
- Martin M.' b'Looney · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 186 not signed on
Sponsors (1)
- b'Looney, Martin M.'
Co-sponsors (0)
None.
Not signed on (186)
186 members have not signed on to this bill.
Show all 186 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- Who sponsors SB 21?
- SB 21 is sponsored by b'Looney, Martin M.'.
- What is the current status of SB 21?
- This bill died with 2017 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track SB 21?
- Track SB 21 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB 21
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB 21
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →